NewsBenzingaSysmex relève ses prévisions de BPA GAAP 2026 de 60,89 JPY à 66,06 JPY ; relève ses prévisions de chiffre d’affaires net pour l’exercice 2026 de 545 milliards JPY à 550 milliards JPY Sysmex relève ses prévisions de BPA GAAP 2026 de 60,89 JPY à 66,06 JPY ; relève ses prévisions de chiffre d’affaires net pour l’exercice 2026 de 545 milliards JPY à 550 milliards JPY Benzinga 2026.11.10 09:12 (GMT+0) Open on Benzinga Other news Bernie Sanders Sounds Alarm On US Affordability Crisis, Says 60% of Americans Live Paycheck to Paycheck: 'Wall Street and the Billionaire Class…' Salesforce Issues Security Advisory On Third-Party Optimizely Script Incident Affecting Certain Salesforce-Branded Sites; Optimizely Scripts Being Confirmed Disabled FBI Reissues Warning About AI-Powered Cyberattacks on Businesses as Crypto Bettors Dismiss AI Link to FAA Outage SpaceX, Meta and Nebius Stand to Benefit From Nvidia’s ‘Fastest Product Ramp’ Yet: Strategist Shay Boloor Explains Why Innate Pharma Reports IPH4502 Phase 1 Data Across 76 Patients: Maximum Tolerated Dose 3.6 Mg/Kg Q3W, Grade 3+ TEAEs In 43.4%, Stomatitis Only Dose-Limiting Toxicity Olema Reports Selective KAT6A Degraders Potently Inhibit Proliferation In Diverse ER+/HER2- Breast Cancer Models, Active In ESR1-Mutant And Wild-Type, Well-Tolerated
Bernie Sanders Sounds Alarm On US Affordability Crisis, Says 60% of Americans Live Paycheck to Paycheck: 'Wall Street and the Billionaire Class…'
Salesforce Issues Security Advisory On Third-Party Optimizely Script Incident Affecting Certain Salesforce-Branded Sites; Optimizely Scripts Being Confirmed Disabled
FBI Reissues Warning About AI-Powered Cyberattacks on Businesses as Crypto Bettors Dismiss AI Link to FAA Outage
SpaceX, Meta and Nebius Stand to Benefit From Nvidia’s ‘Fastest Product Ramp’ Yet: Strategist Shay Boloor Explains Why
Innate Pharma Reports IPH4502 Phase 1 Data Across 76 Patients: Maximum Tolerated Dose 3.6 Mg/Kg Q3W, Grade 3+ TEAEs In 43.4%, Stomatitis Only Dose-Limiting Toxicity
Olema Reports Selective KAT6A Degraders Potently Inhibit Proliferation In Diverse ER+/HER2- Breast Cancer Models, Active In ESR1-Mutant And Wild-Type, Well-Tolerated